NICE Protelos guidance remains unchanged after court-ordered re-examination
This article was originally published in Scrip
Executive Summary
NICE, the health technology institute for England and Wales, is sticking with its original recommendations on Servier's Protelos (strontium ranelate) for preventing osteoporotic fractures. Another final appraisal determination published yesterday follows a legal challenge from Servier and a Court of Appeal ruling that NICE review its guidance and give clear reasoning about why it reached a different conclusion from that of the EMA.